A Phase 2 interventional study of Donepezil in Parkinson's Disease, sponsored by Inje University. Terminated at 1 site in South Korea. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Inje University · Phase 2, Interventional, and Treatment
We cannot enroll the participants
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing donepezil in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Donepezil · Parkinson Disease.
Among the 13 studies testing donepezil in Parkinson Disease, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 6 in phase 2, and was the 7th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →1 of the 13 studies testing donepezil in Parkinson Disease is open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Ages 50–80
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 22 across the 12 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Inje University is the lead sponsor of 93 studies on the registry; 1 is open to participants now.
Inje University has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing donepezil in Parkinson Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study to evaluate the safety and efficacy of high-dose donepezil (23mg) in Parkinson's disease with dementia compared to standard dose donepezil.
This study is open-label, prospective, randomized paralleled study. The investigators evaluate the efficacy of high-dose donepezil in patients with Parkinson's disease with dementia (PDD) who have taken standard donepezil (10mg) for 12 weeks. The participants, who sign the informed consent, are assigned into two groups randomly (high-dose donepezil group and standard donepezil group). All participants will be maintained the medication for 24 weeks and assessed cognitive function at 24 weeks. They will visit to clinic for 3 times (4, 12, 24 weeks) to assess cognitive function and adverse event. After the end of study, all participants were administrated by standard dose donepezil again.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
Drug: Donepezil
Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
Drug: Donepezil
23mg/day for 24 weeks versus 10mg/day for 24 weeks
Also known as: aricept
Korean Mini-Mental State Examination-2 (MMSE-2)
scale for general cognitive function, We used Korean version of MMSE-2 from PAR company
Time frame: 24 weeks
Korean-Instrumental Activities of Daily Living
scales for activities daily living
Time frame: 24 weeks
Clinical dementia rating
scales for activities of daily living
Time frame: 24 weeks
Unified Parkinson's disease rating scale (UPDRS) part 3
scales for motor symptoms in Parkinson's disease
Time frame: 24 weeks
Modified Hoehn & Yahr stage
scales for status of Parkinson's disease
Time frame: 24 weeks
Schwab & England Activities of Daily Living
scales for activities daily living
Time frame: 24 weeks
Caregiver-Administered Neuropsychiatric Inventory
scales for status of caregiver
Time frame: 24 weeks
Global Deterioration Scale
scales for activities of daily living
Time frame: 24 weeks
Korean-Montreal Cognitive Assessment
scales for cognition
Time frame: 24 weeks
Semantic fluency to evaluate neuropsychiatric symptoms
scales for language
Time frame: 24 weeks
Plan to share: Undecided
The record gives a start of Jul 2015, a primary completion of Dec 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2016 → Dec 2016 and completion Dec 2017 → Jun 2017.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
We cannot enroll the participants
We cannot enroll the participants
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil
Inje University